Defining End Points in Phase II Trials of Metastatic Castration-Resistant Prostate Cancer. Re: Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb-Pro): Phase 2 Pilot Study
- PMID: 31409550
- DOI: 10.1016/j.clgc.2019.07.010
Defining End Points in Phase II Trials of Metastatic Castration-Resistant Prostate Cancer. Re: Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb-Pro): Phase 2 Pilot Study
Comment on
-
Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb-Pro): Phase 2 Pilot Study.Clin Genitourin Cancer. 2019 Apr;17(2):e323-e328. doi: 10.1016/j.clgc.2018.12.009. Epub 2019 Jan 2. Clin Genitourin Cancer. 2019. PMID: 30686756 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources